Scientific Article
previous document  unige:145439  next document
add to browser collection

Secondary prevention of Alzheimer's dementia: neuroimaging contributions

Ten Kate, Mara
Ingala, Silvia
Schwarz, Adam J
Fox, Nick C
Chételat, Gaël
van Berckel, Bart N M
Ewers, Michael
Foley, Christopher
show hidden authors show all authors [1 - 21]
Published in Alzheimer's Research and Therapy. 2018, vol. 10, no. 1, 112
Abstract In Alzheimer's disease (AD), pathological changes may arise up to 20 years before the onset of dementia. This pre-dementia window provides a unique opportunity for secondary prevention. However, exposing non-demented subjects to putative therapies requires reliable biomarkers for subject selection, stratification, and monitoring of treatment. Neuroimaging allows the detection of early pathological changes, and longitudinal imaging can assess the effect of interventions on markers of molecular pathology and rates of neurodegeneration. This is of particular importance in pre-dementia AD trials, where clinical outcomes have a limited ability to detect treatment effects within the typical time frame of a clinical trial. We review available evidence for the use of neuroimaging in clinical trials in pre-dementia AD. We appraise currently available imaging markers for subject selection, stratification, outcome measures, and safety in the context of such populations.
Keywords Alzheimer Disease/diagnostic imaging/prevention & controlBiomarkersBrain/diagnostic imaging/pathology/physiopathologyDisease ProgressionHumansLongitudinal StudiesNeuroimaging/methodsSecondary Prevention
PMID: 30376881
Full text
Research group Imagerie per-opératoire multi-modalité en radiologie interventionnelle (949)
(ISO format)
TEN KATE, Mara et al. Secondary prevention of Alzheimer's dementia: neuroimaging contributions. In: Alzheimer's Research and Therapy, 2018, vol. 10, n° 1, p. 112. doi: 10.1186/s13195-018-0438-z

75 hits



Deposited on : 2020-11-27

Export document
Format :
Citation style :